MPM BioImpact’s MoonLake Immunotherapeutics MLTX Stock Holding History

MPM BioImpact’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.3M	Sell	1,606,967 -204,115	-11%	-$3.7M	1.91%	19
2026 Q1	$33.8M	Buy	+1,811,082	New	+$30M	2.61%	13
2025 Q3	–	Sell	-313,571	Closed	-$14.8M	–	45
2025 Q2	$14.8M	Sell	313,571 -2,478	-0.8%	-$101K	2.56%	13
2025 Q1	$12.3M	Buy	316,049 +819	+0.3%	+$35.3K	2.12%	17
2024 Q4	$17.1M	Sell	315,230 -33,833	-10%	-$1.73M	2.42%	15
2024 Q3	$17.6M	Buy	349,063 +5,828	+2%	+$273K	2.64%	13
2024 Q2	$15.1M	Buy	343,235 +47,185	+16%	+$2M	2.35%	11
2024 Q1	$14.9M	Buy	296,050 +1,474	+0.5%	+$80K	2.39%	12
2023 Q4	$17.8M	Buy	294,576 +386	+0.1%	+$19.9K	4.16%	7
2023 Q3	$16.8M	Sell	294,190 -921	-0.3%	-$50.8K	4.48%	7
2023 Q2	$15.1M	Buy	+295,111	New	+$7.94M	3.03%	12

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MPM BioImpact's MLTX Position: Q2 2026 in Review

MPM BioImpact reduced its MoonLake Immunotherapeutics (MLTX) stake by 11% in Q2 2026, selling an estimated $3.7M and leaving 1,606,967 shares worth $31.3M. The position accounts for 1.91% of the portfolio, ranked #19.

MPM BioImpact first reported a position in MLTX in Q2 2023 and has held it in 11 quarters since. The position peaked at $33.8M in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

MPM BioImpact held 1,606,967 shares of MoonLake Immunotherapeutics worth $31.3M as of Q2 2026.
MPM BioImpact sold 204,115 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $3.7M.
MoonLake Immunotherapeutics made up 1.91% of MPM BioImpact's portfolio in Q2 2026, its #19 holding.
MPM BioImpact first reported a position in MoonLake Immunotherapeutics in Q2 2023 and has held it in 11 quarters since.
MPM BioImpact's MoonLake Immunotherapeutics position peaked at $33.8M in Q1 2026.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.